RAPT Therapeutics recently participated in a fireside chat at the UBS Global Healthcare Virtual Conference which held on Monday, May 24, 2021. Participation in the recent health conference
Patients with moderate-to-severe AD who received RPT193 showed a 36.3% improvement from baseline in the Eczema Area and Severity Index (EASI) score, after four weeks of treatment. reported positive topline results from its randomized placebo-controlled Phase 1b clinical trial of RPT193 as monotherapy in 31 patients with moderate-to-severe atopic dermatitis (AD). On June 14, 2021, RAPT Therapeutics, Inc. Positive Results from Phase 1b Trial of RPT193 Monotherapy in Atopic Dermatitis RAPT also providing a 30-day option to purchase up to an additional $18.75 million of its common stock on the same terms and conditions. On June 14, 2021, RAPT Therapeutics, Inc commenced an underwritten public offering of $125 million of its common stock. Participation in the recent health conference.Positive Results from Phase 1b Trial of RPT193 Monotherapy in Atopic Dermatitis.
Proposed Public Offering of Common Stock.
0 kommentar(er)
